Stay updated on CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial
Sign up to get notified when there's something new on the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page.

Latest updates to the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check17 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.5%
- Check24 days agoChange DetectedThe page has removed a citation regarding the characterization of creatine kinase levels in tofacitinib-treated patients with ulcerative colitis, including an erratum reference.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has removed a citation regarding the efficacy and safety of tofacitinib, including an erratum reference.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check60 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 3 study on CP-690,550 for rheumatoid arthritis, while a new revision number has been added.SummaryDifference4%
Stay in the know with updates to CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CP-690,550 Doses vs. Placebo in Arthritis Clinical Trial page.